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Abstract
Background: Serum uric acid (UA) levels have recently been shown to be genetically influenced by common
polymorphisms in the GLUT9 gene in two genome-wide association analyses of Italian and British populations. Elevated
serum UA levels are often found in conjunction with the metabolic syndrome. Hyperuricemia is the major risk factor for
gout and has been associated with increased cardiovascular morbidity and mortality. The aim of the present study was to
further elucidate the association of polymorphisms in GLUT9 with gout and coronary artery disease (CAD) or myocardial
infarction (MI). To test our hypotheses, we performed two large case-control association analyses of individuals from the
German MI Family Study.
Methods and Findings: First, 665 patients with gout and 665 healthy controls, which were carefully matched for age and
gender, were genotyped for four single nucleotide polymorphisms (SNPs) within or near the GLUT9 gene. All four SNPs
demonstrated highly significant association with gout. SNP rs6855911, located within intron 7 of GLUT9, showed the
strongest signal with a protective effect of the minor allele with an allelic odds ratio of 0.62 (95% confidence interval 0.52–
0.75; p = 3.2*10
27). Importantly, this finding was not influenced by adjustment for components of the metabolic syndrome
or intake of diuretics. Secondly, 1,473 cases with severe CAD or MI and 1,241 healthy controls were tested for the same four
GLUT9 SNPs. The analyses revealed, however, no significant association with CAD or with MI. Additional screening of
genome-wide association data sets showed no signal for CAD or MI within the GLUT9 gene region.
Conclusion: Thus, our results provide compelling evidence that common genetic variations within the GLUT9 gene strongly
influence the risk for gout but are unlikely to have a major effect on CAD or MI in a German population.
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Introduction
Gout is the most frequent inflammatory joint disease in men
above 40 years of age [1]. It is characterized by chronic
hyperuricemia, usually defined as serum uric acid (UA) levels
.7 mg/dL, and recurrent attacks of acute arthritis in one-third of
the patients triggered by the release of monosodium urate crystals
into the synovial space [2]. In the majority of patients with primary
gout, hyperuricemia results from inefficient renal excretion, while
in about 10% of cases, hyperuricemia is due to endogenous
overproduction of UA [3]. Gout is an increasingly common
medical problem with an overall prevalence of at least 1% in
Western societies [1]. The reasons for the rise in incidence and
prevalence of gout are closely linked to its known association with
dietary habits, such as overindulgence in food and alcohol, and
with it the intricately connected metabolic syndrome and its
components insulin resistance, abdominal obesity, dyslipidemia,
and arterial hypertension [4,5].
The role of hyperuricemia as an independent risk factor for
coronary artery disease (CAD) and myocardial infarction (MI) has
been discussed controversially for many years since several but not
all epidemiologic studies found an independent association of
elevated serum UA with cardiovascular disease [6–8]. Experi-
mental data to support the hypothesis of a causal relationship
between hyperuricemia and CAD are scarce. However, recent
genetic data might add further insights into the pathophysiology of
hyperuricemia and its possible link to cardiovascular disease. The
availability of large-scale genome-wide association (GWA) studies
using 500,000 or more single nucleotide polymorphism (SNP)
markers equally distributed across the genome, now facilitates
PLoS ONE | www.plosone.org 1 April 2008 | Volume 3 | Issue 4 | e1948identification of susceptibility genes in polygenic and complex
phenotypes, e.g. type 2 diabetes or MI [9–17]. For hyperuricemia,
two very recent GWA studies in an isolated Sardinian population
and in a British cohort identified SNPs in the GLUT9 gene, also
known as SLC2A9, to significantly influence serum UA levels
[18,19]. GLUT9 is a transmembrane glucose transporter that is
highly expressed in liver and kidney [20].
The aims of this study were thus to further assess the association
of GLUT9 polymorphisms in the phenotypic expression of gout
and their possible role in susceptibility to CAD, assuming an
independent influence of hyperuricemia on the development of
cardiovascular disease. For this purpose, we examined two large,
separate case-control samples of individuals from the German MI
Family Study and included also the results from two CAD/MI
GWA studies at the GLUT9 gene region to analyse potential
additive effects.
Materials and Methods
Populations
All individuals of this study participated in the German MI
Family Study (total n = 7,575). Recruitment process, selection
criteria and study details have been reported previously [21,22]. In
brief, we identified families from all parts of Germany with
accumulation of premature MI or severe CAD. Control
individuals were unaffected spouses of MI family members and
had no genetic relationship to cases.
The Ethics committee of the University of Regensburg
approved the study protocol and all participants gave their written
informed consent at the time of inclusion and again at the time of
follow-up investigations. The study was in accordance with the
principles of the current version of the Declaration of Helsinki.
Phenotyping
The baseline home visit was performed by a physician and
included a standardized questionnaire, physical examination, and
biochemical analyses. A standardized follow-up interview regard-
ing new medical events was carried out by specially trained
telephone interviewers after two and five years. Cardiovascular
events at study entry and follow-up were validated by reviewing
medical records.
The phenotype gout was carefully established using two levels of
evidence: 1. medical history readings at time of inclusion, two-year
and five-year follow-up interview; and 2. self-reported history of
gout. The diagnosis of MI was established according to the
MONICA (Monitoring Trends and Determinants in Cardiovas-
cular Disease) diagnostic criteria (http://www.ktl.fi/publications/
monica/manual/index.htm). Severe CAD was defined as treat-
ment with percutaneous coronary intervention or coronary artery
bypass graft. Resting blood pressure was taken according to
MONICA guidelines after participants had been resting in a
sitting position [23]. Hypertension was defined as blood pressure
$140/90 mm Hg or ongoing antihypertensive therapy. Body
weight was determined with subjects wearing light clothing. Body
mass index (BMI) was calculated as weight in kilograms divided by
the square of height in meters. Sampling of serum was carried out
from non-fasting individuals. Serum levels of low-density lipopro-
tein cholesterol (LDL-C) and high-density lipoprotein cholesterol
(HDL-C) were measured by standard enzymatic methods.
Hypercholesterolemia was defined as LDL-C $160 mg/dL or
intake of lipid lowering medication. History of diabetes mellitus or
intake of antidiabetic medication was used to define type 2
diabetes. Smoking was defined as current or former smoking habit.
Case-control samples
A total of n = 665 individuals (n = 479 males, n = 186 females)
with the diagnosis of gout were selected from the German MI
Family Study. All gout cases fulfilled the above mentioned criteria
for ‘‘gout’’. Controls were unrelated individuals from our German
MI Family Study who did neither have any indication for gout nor
were they medicated with uricostatics or uricosuric agents at any
time during follow-up.
We carefully matched the gout-free controls (n = 665)
according to age and gender to the gout cases. Further phenotypic
details are shown in Table 1.
Futhermore, a large case-control sample was established from
the German MI Family Study including 1,473 CAD/MI cases
(856 male, 617 female) and 1,241 unrelated CAD/MI-free control
individuals (336 male, 905 female). Cardiovascular risk factors and
phenotypic details are summarized in Table 2.
SNP selection and genetic analyses
Four GLUT9 SNPs were selected from a public reference
database (dbSNP, http://www.ncbi.nlm.nih.gov/SNP/) based on
the following criteria: (1) evidence for significant association with
serum UA levels from two recent publications (rs6855911 and
rs7442295) [18,19], (2) minor allele frequency of .0.10 in a
Caucasian population, (3) evidence of validation status, and (4)
compatibility with our genotyping platform. To allow determina-
tion of the extend of LD beyond the boundaries of the gene, one
SNP in the 59 intergenic region was included.
Genomic DNA was isolated from whole blood samples using the
PureGene DNA Blood Kit (Gentra, Minneapolis, MN, USA).
DNA samples were genotyped using 59 exonuclease TaqManH
technology (Applied Biosystems, Foster City, CA, USA). For each
genotyping experiment 10 ng DNA was used in a total volume of
5 ml containing 16 TaqManH Genotyping Master Mix (Applied
Biosystems). PCR reaction and post-PCR endpoint plate read was
carried out according to the manufacturer’s instructions using the
Applied Biosystems 7900HT Real-Time PCR System. Sequence
Detection System software version 2.3 (Applied Biosystems) was
used to assign genotypes applying the allelic discrimination test.
Case and control DNA was genotyped together on the same plates
with duplicates of samples (15%) to assess intraplate and interplate
genotype quality. No genotyping discrepancies were detected.
Assignment of genotypes was performed by a person without
knowledge of the proband’s affection status. Additionally,
comparison between genotype calls from TaqMan assays and
Affymetrix GeneChipH Human Mapping 500K Array Set were
carried out in 288 DNA samples on all four SNPs (rs6855911,
rs7442295, rs6449213, and rs12510549). Again, no discrepancies
were found. SNPs were mapped to the GLUT9 gene according to
NM_001001290 (position on human genome build 18: chromo-
some 4; 9,436,948-9,650,970).
Genome-wide data from two recently published screens for
polymorphisms associated with CAD or MI were employed to
survey the complete GLUT9 gene region [12]. All successfully
genotyped SNPs on the Affymetrix GeneChipH Human Mapping
500K Array Set on chromosome 4 in the GLUT9 region with
500 kb on either side of the gene (position 8,936,948 and
10,150,970; human genome build 18) were included (Fig. 1).
Data of the HapMap phase II release 22 data were used to
assess linkage disequilibrium (LD) patterns of the GLUT9 gene
region [24].
Statistical analyses
To determine whether the genotypes of cases and controls of all
GLUT9 SNPs deviated from Hardy-Weinberg equilibrium, actual
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Variable CAD cases (n = 1,473) CAD-free controls (n = 1,241) p-Value
Gender, % male (n) 58.1 (856) 27.1 (336) ,0.0001
Age at inclusion, years (range) 60.268.5 (32–90) 56.469.9 (29–84) ,0.0001
Age at first CAD event, years (range) 54.569.1 (24–89) - -
MI, % (n) 75.6 (1,114) - -
Gout, % (n) 15.5 (228) 8.8 (109) ,0.0001
Hypercholesterolemia
a,%( n) 83.4 (1,228) 29.3 (363) ,0.0001
Lipid lowering medication, % (n) 66.7 (982) 38.2 (474) ,0.0001
LDL-C, mg/dl 149.4642.6 146.1634.9 0.0313
HDL-C, mg/dl 51.4613.8 61.6615.3 ,0.0001
Hypertension
b,%( n) 94.4 (1,390) 53.9 (669) ,0.0001
Antihypertensive therapy, % (n) 89.3 (1316) 35.0 (434) ,0.0001
Systolic blood pressure, mm Hg 140.0620.4 132.6618.2 ,0.0001
Diastolic blood pressure, mm Hg 82.6610.4 81.469.8 0.0054
Type 2 diabetes
c,%( n) 11.6 (171) 4.2 (52) ,0.0001
Smoking
d,%( n) 62.7 (924) 48.1 (597) ,0.0001
BMI, kg/m
2 27.363.6 26.564.2 ,0.0001
Values denote means 6 standard deviations unless indicated otherwise. CAD, coronary artery disease; MI, myocardial infarction; LDL-C, low-density lipoprotein
cholesterol; HDL-C, high-density lipoprotein cholesterol; BMI, body mass index.
aDefined as LDL-C $160 mg/dL or intake of lipid lowering medication.
bDefined as blood pressure $140/90 mm Hg or ongoing antihypertensive therapy.
cDefined as history of diabetes mellitus or intake of antidiabetic medication.
dFormer or current smoking habit.
doi:10.1371/journal.pone.0001948.t002
Table 1. Characteristics of gout case and control study sample.
Variable Gout cases (n = 665) Gout-free controls (n = 665) p-Value
Age at inclusion, years (range)
a 59.968.6 (29–84) 59.868.4 (31–79) n. s.
Gender, % male (n)
a 72.0 (479) 72.0 (479) n. s.
Medication with diuretics, % (n) 35.0 (233) 23.3 (155) ,0.0001
MI or severe CAD, % (n) 67.5 (449) 65.9 (438) n. s.
Hypercholesterolemia
b,%( n) 72.6 (483) 69.2 (460) n. s.
Lipid lowering medication, % (n) 48.6 (323) 47.1 (313) n. s.
LDL-C, mg/dl 150.1640.2 148.4639.7 n. s.
HDL-C, mg/dl 49.7613.8 53.4615.0 ,0.0001
Hypertension
c,%( n) 88.6 (589) 84.5 (562) n. s.
Antihypertensive therapy, % (n) 78.4 (521) 72.8 (484) n. s.
Systolic blood pressure, mm Hg 140.3619.0 137.0618.3 0.0019
Diastolic blood pressure, mm Hg 84.1610.2 82.0610.2 0.0003
Type 2 diabetes
d,%( n) 17.7 (118) 10.5 (70) ,0.0001
Smoking
e,%( n) 67.2 (447) 65.1 (433) n. s.
BMI, kg/m
2 28.363.8 26.963.3 ,0.0001
Values denote means 6 standard deviations unless indicated otherwise. n. s., not significant; CAD, coronary artery disease; MI, myocardial infarction; LDL-C, low-density
lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; BMI, body mass index.
aMatching parameter.
bDefined as LDL-C $160 mg/dL or intake of lipid lowering medication.
cDefined as blood pressure $140/90 mm Hg or ongoing antihypertensive therapy.
dDefined as history of diabetes mellitus or intake of antidiabetic medication.
eFormer or current smoking habit.
doi:10.1371/journal.pone.0001948.t001
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x
2-test. Differences in allele frequencies between dichotomous
traits were calculated employing the same method. Genotypes
were coded for both dominant and recessive effects (genotype
22+12 versus 11 and genotype 22 versus 11+12, respectively, with
the minor allele coded as 2). The additive genetic model was
calculated using Armitage’s trend test. Multiple logistic regression
analysis was used to examine the association of GLUT9 SNPs with
either phenotype (gout or CAD/MI) allowing adjustment for
relevant covariates (Tables 1, 2). Differences in continuous
variables between groups were calculated using a two-tailed
unpaired t-test. Prevalence odds ratios (OR) with their 95%
confidence intervals (CI) were reported. A two-sided p-value
#0.05 was considered statistically significant.
Association analyses were performed using JMP IN 7.0.1 (SAS
Institute Inc, Cary, NC, USA) and PLINK v1.00 [25]. For
haplotype analysis and permutation testing PLINK v1.00 [25] and
HaploView v4.0 [26] were employed. Power analysis was carried
out using G*Power 3.0.8 [27].
Results
Population characteristics
In our first case-control cohort, gout cases (n = 665) were
matched for age and gender to control individuals (n = 665).
Prevalence of cardiovascular risk factors and cardiovascular disease
was high in both, gout cases and gout-free controls. Gout cases were
more often treated with diuretics as compared to controls. In
addition, in gout cases, the prevalence of type 2 diabetes and
increased BMI was higher, whereas in gout-free controls HDL-C
levels were elevated. However, we found no significant difference in
number of reported MI or CAD events between gout cases (67.5%
CAD/MI) and gout-free controls (65.9% CAD/MI). Prevalence of
hypercholesterolemia, hypertension and smoking were equally
distributed between the two groups (Table 1).
In our second, large case-control sample for CAD/MI the
incidence of established cardiovascular risk factors, such as male
gender, type 2 diabetes, hypercholesterolemia, hypertension and
smoking, as well as increased BMI, was higher in CAD/MI cases
(n =1 , 4 7 3 )a sc o m p a r e dt oc o n t r o l s( n =1 , 2 4 1 )( T a b l e2 ) .
Interestingly, we also found more individuals suffering from gout in
our CAD/MI cases compared to CAD/MI-free controls (Table 2).
Genetic analyses
The cohorts were genotyped for markers rs6855911, rs7442295,
and rs6449213 located in GLUT9 intron 7, 6, and 4, respectively.
Additionally, rs12510549, 235 kb upstream of GLUT9, was
included in the analysis (Table 3). All SNPs fulfilled our criteria
of at least 98.5% call rate in all sub-samples. Marker rs6855911
and rs7442295 were reported to be strongly associated with serum
UA levels [18]. Pairwise LD analysis showed decreasing r
2-values
from rs6855911 to rs12510549 although LD between the four
markers remained on an overall high level of r
2$0.45 (Table 3).
Association analysis of GLUT9 SNPs in the gout case-
control sample. Genotype distributions and allele frequencies
in gout case-control cohort are shown in Table 4. There was no
significant deviation from Hardy-Weinberg equilibrium (HWE) in
gout-free controls (p = 0.43, p = 0.45, p = 0.34, and p = 0.21 for
rs6855911, rs7442295, rs6449213, and rs12510549, respectively).
In contrast, there was a deviation from the HWE in gout cases (p
= 0.04, p = 0.01, p = 0.01, and p = 0.02 for rs6855911,
rs7442295, rs6449213, and rs12510549, respectively).
Strong association with gout was observed for all four markers
(Table 4). The highest significance level of p = 2.9*10
27 was
detected for genotype distribution of marker rs6855911. We found
a protective effect of the minor allele with an allelic OR of 0.62
(95% CI 0.52–0.75) (Table 4). Multivariate logistic regression
analysis adjusting for BMI, type 2 diabetes, and medication with
diuretics even increased the significance of the association (p =
4.6*10
28). Hence, effect of marker rs6855911 on susceptibility to
Figure 1. Schematic representation of a ,1,214 kb region on human chromosome 4p16.1 (position 8,936,948 and 10,150,970;
human genome build 18) used for association analyses. Position numbers are given on top. (A) Relative positions of SNPs analyzed in this
study. GWA SNPs from WTCCC and Cardiogenics CAD/MI case-control study are shown above the four SNPs genotyped in this work (gt SNPs). From
left to right: rs6855911, rs7442295, rs6449213, and rs12510549. (B) Graphic illustration of genes in this genomic region. Relative positions of RefSeq
genes with gene names are presented. Exons are depicted as vertical blocks and orientation of genes is indicated by arrows on the horizonal lines
representing introns. GLUT9 gene is highlighted with bold letters. (C) Delineation of LD structure. Pairwise r
2-values between markers from HapMap
phase II release 22 for the CEPH (CEU) sample were calculated and presented. Red denotes perfect LD with r
2=1 and decreasing r
2-values are shown
in brighter color with white representing r
2=0.
doi:10.1371/journal.pone.0001948.g001
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several components of the metabolic syndrome.
In addition to allele frequency and genotype distribution, we
analyzed additive, dominant and recessive genetic models with no
substantial increase in significance (Table 5).
According to the high LD between the SNPs, four-marker
haplotypes were constructed spanning a 340-kb genomic region.
Nine of the 4
2 possible haplotypes could be observed with only two
(AATT and GGCC) having frequencies .0.05 in cases and controls
of the gout sample. The most common haplotype AATT (i. e. major
allele from each marker) was less frequently present in healthy
individuals as compared to patients with gout (frequency in gout-
free controls = 0.691; frequency in gout cases = 0.780), i. e.
representing a risk haplotype, resulting in a p-value of 2.2*10
27.T h e
secondcommonhaplotype(GGCC)codesfor a protective haplotype
with frequency in controls of 0.183 and frequency in cases of 0.126,
respectively (p = 4.5*10
25). After adjustment for BMI, type 2
diabetes, and medication with diuretics in a multivariate logistic
regression analysis, the association results remained significant (p =
1.3*10
27 for AATT and p = 2.9*10
25 for GGCC).
Both, single marker and haplotype association analysis
remained significant after 100,000 permutations. No permutation
x
2-value exceeded highest observed x
2-value.
Separate analyses in females and males revealed similar odds
ratios in allele frequency comparisons but slightly higher
significance levels in males (Table 6) than in females (Table 7).
Association analysis of GLUT9 SNPs in the CAD/MI case-
control sample. Our power calculation indicated that at a
significance level of 0.05 and with a two-sided alternative
hypothesis, our CAD/MI sample with n = 1,473 cases and n =
1,241 CAD-free controls (Table 2) had more than 97% power to
detect a significant association with an assumed OR of 1.4
between the tested polymorphisms and the phenotype. HWE
criteria for the four genotyped markers were fulfilled in CAD/MI
cases and CAD/MI-free controls (p.0.4).
No association with CAD was observed for any of the analyzed
SNPs (Table 8). To evaluate the impact of a more stringent
phenotype definition, we included only MI cases (n = 1,114) as a
sub-sample of CAD patients in a separate analysis. Again, no
significant difference in allele or genotype frequencies of the four
Table 3. SNP marker used in analysis.
SNP Position
b Major allele (1) Minor allele (2) Function Pairwise linkage disequilibrium (r
2)
a
rs685591 rs7442295 rs6449213
rs6855911 9,545,008 A G Intron 7 -
rs7442295 9,575,478 A G Intron 6 0.815 -
rs6449213 9,603,313 T C Intron 4 0.660 0.809 -
rs12510549 9,885,565 T C 59 intergenic 0.450 0.547 0.664
acalculated in gout case-control sample with 1,304 individuals without any missing genotype.
bon chromosome 4 (hg18).
doi:10.1371/journal.pone.0001948.t003
Table 4. Association analysis results in gout case-control sample.
SNP Gout case genotypes Gout-free control genotypes Genotypic Allelic Allelic OR
11 12 22 MAF 11 12 22 MAF p-value p-value (95% CI)
rs6855911 423 220 16 0.191 350 255 54 0.275 2.9*10
27 3.2*10
27 0.62 (0.52–0.75)
rs7442295 449 200 9 0.166 389 230 40 0.235 2.3*10
26 8.3*10
26 0.65 (0.53–0.78)
rs6449213 469 181 6 0.147 421 207 32 0.205 1.6*10
25 8.9*10
25 0.67 (0.55–0.82)
rs12510549 459 192 9 0.159 392 238 26 0.221 9.9*10
25 5.1*10
25 0.67 (0.55–0.81)
MAF: minor allele frequency; numbers of genotypes (11, 12, 22) according to alleles from Table 3.
doi:10.1371/journal.pone.0001948.t004
Table 5. Results from different genetic models in gout case-control sample.
SNP
Dominant (22+12 vs. 11)
p-value
Recessive (22 vs. 12+11)
p-value
Additive
p-value
rs6855911 4.4*10
25 3.1*10
26 2.9*10
27
rs7442295 5.1*10
24 6.6*10
26 6.8*10
26
rs6449213 2.8*10
23 2.0*10
25 7.9*10
25
rs12510549 2.0*10
24 3.4*10
23 2.9*10
25
doi:10.1371/journal.pone.0001948.t005
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= 1,241) was observed (e. g. genotype distribution; rs6855911, p
= 0.42; rs7442295, p = 0.27; rs6449213, p = 0.70; rs12510549, p
= 0.81). Multivariate logistic regression analysis adjusting for
cardiovascular risk factors (age at first manifestation, male gender,
type 2 diabetes, hypercholesterolemia, hypertension, smoking, and
BMI) both on single SNPs and haplotypes in CAD/MI case-
control sample did not reveal positive association results (data not
shown). Separate analysis for male and female individuals did not
point to gender-specific effects of the four SNPs and CAD/MI in
trend test (p.0.18).
To gain maximum power for detection of even small effects, we
included all appropriate individuals from our German MI Family
Study in the CAD/MI case-control sample. This included an
overlap of 220 individuals from gout case sample in CAD/MI case
sample, 337 individuals from gout control sample in CAD/MI
case sample, 108 individuals from gout case sample in CAD/MI
control sample, and 217 individuals from gout control sample in
CAD/MI control sample, respectively. After an initial round of
association testing with CAD/MI, we excluded all overlapping
individuals from the analysis. Again, in remaining n = 916 CAD/
MI cases compared to n = 916 controls neither SNPs nor
haplotypes achieved statistical significance, even after adjustment
for age of first manifestation of CAD/MI, male gender, type 2
diabetes, hypercholesterolemia, hypertension, smoking, and BMI
(data not shown).
To assess the possibility that other markers located within or
close to the GLUT9 gene could exert influence on susceptibility to
CAD or MI, we analyzed the data from two recently conducted
GWA studies [12]. Both, from British (WTCCC) and German
(Cardiogenics) case-control samples, p-values were obtained for
association with CAD/MI (WTCCC) and MI (Cardiogenics). A
total of 292 SNP markers located in GLUT9 gene region (214 kb)
and a more extended region of 1,000 kb around the GLUT9 gene
were analyzed (Fig. 1). None of the SNPs showed association at a
p,0.05 with CAD/MI in the WTCCC and Cardiogenics cohorts.
Table 6. Association analysis results in male gout case-control sample.
SNP Gout case genotypes
Gout-free control
genotypes Genotypic Additive Allelic Allelic OR
11 12 22 MAF 11 12 22 MAF p-value p-value p-value (95% CI)
rs6855911 297 166 11 0.198 246 192 37 0.280 3.1*10
25 2.1*10
25 3.0*10
25 0.64 (0.51–0.79)
rs7442295 316 151 6 0.172 276 171 28 0.239 1.1*10
24 2.5*10
24 3.3*10
24 0.66 (0.53–0.83)
rs6449213 331 136 5 0.155 298 156 22 0.210 1.0*10
23 1.5*10
23 1.9*10
23 0.69 (0.54–0.87)
rs12510549 324 142 8 0.167 279 176 17 0.223 6.0*10
23 1.5*10
23 2.2*10
23 0.70 (0.56–0.88)
MAF: minor allele frequency; numbers of genotypes (11, 12, 22) according to alleles from Table 3.
doi:10.1371/journal.pone.0001948.t006
Table 7. Association analysis results in female gout case-control sample.
SNP Gout case genotypes Gout-free control genotypes Genotypic Additive Allelic Allelic OR
11 12 22 MAF 11 12 22 MAF p-value p-value p-value (95% CI)
rs6855911 126 54 5 0.173 104 63 17 0.264 9.4*10
23 4.0*10
23 2.9*10
23 0.58 (0.41–0.83)
rs7442295 133 49 3 0.149 113 59 12 0.223 n. a. 8.5*10
23 7.4*10
23 0.60 (0.41–0.87)
rs6449213 138 45 1 0.128 123 51 10 0.193 n. a. 0.018 0.016 0.61 (0.41–0.91)
rs12510549 135 50 1 0.140 113 62 9 0.217 n. a. 5.1*10
23 5.8*10
23 0.59 (0.40–0.86)
MAF: minor allele frequency; numbers of genotypes (11, 12, 22) according to alleles from Table 3.
n. a.: not applicable due to low counts of minor allele for x
2.
doi:10.1371/journal.pone.0001948.t007
Table 8. Association analysis results in CAD case-control sample.
SNP CAD case genotypes CAD-free control genotypes Genotypic Allelic Allelic OR
11 12 22 MAF 11 12 22 MAF p-value p-value (95% CI)
rs6855911 808 556 98 0.257 709 455 67 0.239 0.275 0.129 1.10 (0.97–1.25)
rs7442295 884 496 79 0.224 775 415 49 0.207 0.176 0.128 1.11 (0.97–1.26)
rs6449213 939 462 61 0.200 820 374 43 0.186 0.431 0.201 1.09 (0.95–1.25)
rs12510549 901 497 61 0.212 788 397 48 0.200 0.514 0.270 1.08 (0.94–1.23)
MAF: minor allele frequency; numbers of genotypes (11, 12, 22) according to alleles from Table 3.
doi:10.1371/journal.pone.0001948.t008
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This study investigated the relationship between four common
sequence variants and haplotypes within the GLUT9 gene region
with gout and CAD/MI in two German case-control samples. We
were led to pursue the GLUT9 gene because of very recent findings
that sequence variants in this gene significantly influence the
serum UA levels in Italian and British populations [18,19].
The prevalence for gout in Germany is 1.4% [28], whereas
lifestyle plays an important role on its epidemiology [29].
Hyperuricemia, i. e. high serum UA levels, are associated with
the occurrence of gout with some pathophysiologic details still
unresolved [30]. The role of gout as a risk factor for CAD and MI
was recently demonstrated in epidemiologic data [31]. This
prospective study revealed that men with gout had a 59% higher
risk of nonfatal MI than men without gout [31].
However, it is still controversial whether hyperuricemia
independently predicts cardiovascular events. It is furthermore
unclear whether it relates to cardiovascular disease by a complex
interaction with several classical risk factors, such as arterial
hypertension, obesity, hypercholesterolemia and insuline resis-
tance, all of which are components of the metabolic syndrome
[32,33].
The overall cardiovascular risk is caused by factors like smoking,
hypercholesterolemia, hypertension, type 2 diabetes, abdominal
obesity, psychosocial factors, physical activity, and nutrition [34].
Additionally, genetic variations modulate not only some of these
classical cardiovascular risk factors but act also in a complex
manner [35]. Alleles directly influencing susceptibility to CAD or
MI in a still unknown fashion were consistently found in three
recent GWA studies [10–12].
To our knowledge, the present study offers the first case-control
association analysis of common GLUT9 variants with the
qualitative phenotypes gout and CAD/MI. We report strong
association between all four GLUT9 SNPs and gout consistently
showing a protective effect of the minor alleles with an odds ratio
of 0.62. The effect was not influenced by multivariate adjustment
for cardiovascular risk factors or metabolic traits and, importantly,
intake of diuretic medication pointing to a largely independent
genetic effect. Our results are consistent with the findings of Li et
al., who demonstrated a significant negative additive effect of
about 0.40 mg/dL of GLUT9 polymorphisms rs6855911 and
rs7442295 on serum UA levels resulting from a protective effect of
the minor alleles [18]. Therefore, these SNP markers could be
helpful for stratification of risk for gout in the general population.
Although gout is generally regarded as a disease that is easy to
diagnose and has an effective treatment, in less typical cases –
particularly in the elderly – the strictly clinical diagnosis becomes
less accurate [36]. Misdiagnosing of gout or gouty arthritis as
osteoarthritis, rheumatoid arthritis, septic arthritis, or other
rheumatic conditions may lead to inappropriate treatment and
result in unnecessary morbidity. To support the diagnosis of these
atypical presentations genetic testing could be beneficial, help to
prevent clinical mismanagement and avoid costs. Maybe, the
GLUT9 gene may even provide a new therapeutic target for
hyperuricemia and gout in the future.
For all genotyped markers, we found moderate deviation from
HWE in gout cases. Generally, deviations from HWE can point to
either a sampling bias or population stratification. Whereas HWE
deviations in a control sample suggest the possibility of genotyping
errors, HWE deviations in cases can also be the result of true
association [37]. We deliberately focused on common sequence
variants with MAF between 15 and 20%, as it is more likely that
these frequent variants play a role in the general population. Thus,
with the MAF being this high, our sample with n = 665 gout cases
and n = 665 controls had enough power (.80% with an assumed
change of 40% in OR) to detect a true effect.
Additional evidence for a reliable positive association between
GLUT9 SNPs and gout came from analysis of the Framingham
SNP Health Association Resource (SHARe) posted on the NCBI
dbGaP website at http://www.ncbi.nlm.nih.gov/projects/gap/
cgi-bin/study.cgi?study_id=phs000007.v2.p1. Here, n = 1,345
adult participants of the largest 310 pedigrees in the Framingham
Heart Study were genotyped with the Affymetrix 100K GeneChip
[38]. Age, sex and BMI adjusted p-values for the phenotype gout
(defined as history of gout at any examination cycle) were available
(accession: pha001406.1). However, the four SNPs analyzed in our
study (rs6855911, rs7442295, rs6449213, and rs12510549) were
not included on the Affymetrix 100K GeneChip. For GLUT9,
marker rs10516195 located in intron 3 near to and in LD with our
SNPs (7.6 kb upstream from rs6449213) showed high significance
with gout (p = 3.7*10
28).
In our study, we found stronger significance between genotyped
markers and gout in males than in females. However, odds ratios
have the same order of magnitude with a risk reduction of about
40%. It is known that serum UA levels and incidence of gout are
higher in males, but tend to equalize with increasing age [39]. In
our study, the relatively small female sample size (n = 186 cases
and n = 186 controls, respectively) limits the conclusion of gender-
specific effects mediated by polymorphisms in GLUT9 gene on
gout.
Also, SNP rs12510549, located 235 kb upstream to GLUT9
showed significant association with gout in our study. HapMap
data describe a large LD block covering two-thirds of GLUT9 and
a large proportion of upstream intergenic sequence, including
WDR1 gene [24] (Fig. 1). It cannot be excluded that the gene
encoding WDR1, also known as actin interacting protein 1 (AIP1)
contributed at least to a minor portion to the association signals for
serum UA levels and gout. Thus far, no functional variants,
explaining the effect on serum UA levels in GLUT9 gene, could be
identified by Li et al. [18]. The four SNPs within the GLUT9 gene
region analysed in our study were located in intronic and
intergenic regions. A possible effect of a functional variant beyond
changes in amino-acid composition of translated protein could
lead to altered gene expression, which can be modulated by the
concerted action of multiple transcription factors over long
distances and, thus, be influenced by multiple SNPs [40]. It could
be shown that gene regulatory elements are harboured in non-
coding and intergenic regions [41]. The biological function of the
GLUT9 gene is not fully understood yet. It is known, however, that
GLUT9 plays an important role as transmembrane sugar
transporter and is highly expressed in liver and kidney tubules
[20,42]. Therefore, altered function or expression of GLUT9 in
liver may interfere with UA metabolism and increase production
of UA, whereas an effect in kidney could lead to reduced renal UA
excretion. With elevated serum UA levels, the risk for gout
increases considerably, which can be seen in the association
analysis of GLUT9 gene polymorphisms with the phenotype
‘‘gout’’. However, without the knowledge of serum UA levels in
our study, we cannot exclude more direct effects of GLUT9 gene
variants on gout.
In the second case-control analysis, the hypothesis of a causal
link of hyperuricemia and elevated risk for CAD or MI was
addressed. In a large case-control study, we found no association
of the markers in GLUT9 with CAD/MI. In addition, GWA
studies on CAD/MI revealed no significant association signal of
SNP markers in the extended GLUT9 region. Hence, it is unlikely
for polymorphisms in GLUT9 to be major contributors to the risk
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and CAD via genetic variations within the GLUT9 gene appears
doubtful. No difference in the prevalence of CAD/MI in the gout
case-control sample was observed: 67.5% and 65.9% of the gout
cases and gout-free controls, respectively, were affected by CAD/
MI (Table 1). However, the reverse was not true for the CAD/MI
sample (Table 2). Here, the prevalence of gout and of all
components of the metabolic syndrome studied was significantly
higher in CAD/MI cases than in CAD/MI-free controls. Due to
the study design, we did not dispose of prevalence data for gout
until the time point of inclusion and not at the time of the first
CAD/MI event. Therefore, prospective analyses on the role of
gout on the development of CAD cannot be derived from our data
and only descriptive evidence for the relationship between gout
and CAD can be given. In addition, it has to be mentioned that
our sample provides a special subgroup of the general population
and even of CAD patients. This is caused by the inclusion criteria
of the German MI Family Study, where particularly high risk
individuals from MI families were recruited (index patient
suffering from MI before the age of 60 years and further siblings
with severe manifestation of CAD/MI agreeing to participate in
the study).
Several limitations of our study have to be considered. The gout
phenotype was assessed retrospectively from patients records and
medical history without knowledge of serum UA levels. However,
we combined two levels of evidence, namely medical history
readings at time of inclusion and at two-years and five-years
follow-up interview together with self-reported history of gout. We
only included control individuals without history of gout and
without intake of uricostatics or uricosuric agents. The two most
confounding effects on association with gout - age and gender -
were excluded by carefully matching these parameters between
gout cases and gout-free controls. However, in the CAD/MI
sample an imbalance on gender existed due to the selection
approach of the control individuals in our German MI Family
Study (relatives of cases for a disease having a much higher
prevalence in males). Therefore, we adjusted for male gender and
other cardiovascular risk factors with no increase in significance.
Additionally, the two analyzed GWA studies on CAD/MI
included a more balanced gender distribution between cases and
controls (e. g. in the Cardiogenics MI sample 591 male cases and
284 female cases, respectively, were compared with 813 male
controls and 831 female controls, respectively). Here, separate
analysis of the four SNPs (rs6855911, rs7442295, rs6449213, and
rs12510549) revealed no association with MI, even after
adjustment for male gender.
In conclusion, our study demonstrates strong evidence that
polymorphisms in GLUT9 gene are associated with increased
susceptibility to gout. Furthermore, these SNPs are unlikely to play
a causal role in the pathogenesis of CAD or MI. Additional
functional analyses are warranted to further elucidate the role of
GLUT9 in the pathophysiology of hyperuricemia and gout.
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